港股異動 | 獲券商看好 藥明康德H股漲逾9%A股漲停
格隆匯10月31日丨藥明康德(2359.HK)現漲9.22%,報92.4港元,暫成交8902萬港元,最新總市值1691億港元;公司A股漲停,報94.07元,股價再創階段新高。公司昨日公告稱,前三季度營業收入92.79億元人民幣,同比增長34.06%;歸屬於上市公司股東的淨利潤17.65億元,同比下降8.46%;扣非後歸母淨利潤17.14億元,同比增36.88%。中信建投研報指,預計公司2019年-2021年收入增速分別為31.0%、30.3%和 29.2%,對應歸母淨利潤分別為21.2 億元、26.6億元和34.4億元,相應增速分別為-6.2%、25.4%和 29.4%,預計公司剔除股權激勵、匯兑損益、公允價值變動、聯合營企業投資收益後經調整的non-IFRS歸母淨利潤增速與收入增速基本匹配,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.